ArticleCellular oncology (Dordrecht, Netherlands)2026
Targeting VCP with V8 suppresses glioblastoma development via formation of aggregates and disruption of mitophagy flux.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GBM) is a highly lethal malignancy with limited therapeutic options. Identifying effective therapeutic targets and developing corresponding drugs remain unmet clinical needs. PURPOSE: This study aimed to investigate the expression and role of VCP in GBM, as well as the anti-GBM activity and underlying mechanisms of V8, a wogonin-derived small molecule.
methodsThe expression of VCP in GBM cells and its correlation with glioma malignancy were analyzed. The binding of V8 to VCP was verified, and the effects of V8 on VCP function, cellular proteostasis, mitochondrial status, mitophagy process, and lysosomal integrity were evaluated to clarify its anti-GBM mechanisms.
resultsVCP is highly expressed in GBM cells and correlates with glioma malignancy. V8 exerts anti-GBM activity by binding to the D1 domain of VCP, with dual mechanisms of action: (1) Aggresome-mediated proteostatic crisis: V8 immobilizes VCP, triggers protein aggregates in the cytoplasm and mitochondria, and induces mitochondrial injury; (2) Disruption of mitophagy flux: VCP inhibition-induced damaged mitochondria recruit mitophagy receptors (BNIP3/P62/TAX1BP1) to initiate mitophagy, and VCP directly interacts with PRKN to promote mitophagy initiation. However, V8 concurrently impairs lysosomal integrity, thereby obstructing mitophagy flux and ultimately leading to GBM cell death. Additionally, VCP was found to not only maintain mitochondrial proteostasis but also preserve lysosomal integrity to facilitate the clearance of damaged mitochondria via mitophagy.
conclusionTargeting VCP with inhibitors such as V8 induces mitochondrial dysfunction, effectively suppresses GBM cell viability, and holds potential for GBM therapy. VCP may serve as a promising therapeutic target for GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.